Impact of GDMT implementation on albuminuria in HFrEF

29 August 2025 (08:15 - 09:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Noel Panagiotides

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail

Impact of rhythm control in wild-type transthyretin cardiac amyloidosis and atrial fibrillation: a retrospective analysis

Doctor J. Vogel (Essen, DE)

Abstract Slides Video

Presentation thumbnail

Clinical features of chronic active myocarditis in patients with heart failure and reduced left ventricular ejection fraction

Doctor M. Ruiz Cano (Bad Oeynhausen, DE)

Abstract Slides Video

Presentation thumbnail

Apical sparing and clinical parameters in patients with histologically confirmed transthyretin amyloidosis

Mr T. Krammer (Regensburg, DE)

Abstract Slides Video

Presentation thumbnail

Impact of tafamidis on sleep-disordered breathing in transthyretin cardiomyopathy

Miss Y. Ferrari Chen (Pisa, IT)

Abstract Slides Video

Presentation thumbnail

Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2

Ms J. Locatelli Bet (Rio Do Sul, BR)

Abstract Slides Video

Access the full session

Session thumbnail

Novel treatment approaches in heart failure and cardiomyopathies

The Event

Event poster

ESC Congress 2025

29 August 2025 08:15 CET

You may be interested in

Congress Presentation

The presence and prognostic effect of albuminuria in light of the rapid-up titration programme of guideline-directed medical therapy in heart failure

Congress Presentation

Real world data on adopting guideline directed medical therapy post 2021 ESC HF guidelines and effect on renal function.

Congress Presentation

Renal function in STRONG-HF

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources